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ABSTRACT 
 
The human microsomal epoxide hydrolase, a single enzyme, has to detoxify a broad range of 
structurally diverse, potentially genotoxic epoxides that are formed in the course of xenobiotic 
metabolism. The enzyme has developed a unique strategy to combine a broad substrate 
specificity with a high detoxification efficacy, by immediately trapping the reactive 
compounds as covalent intermediates and by being expressed at high levels for high trapping 
capacity. Computer simulation and experimental data as well as existing epidemiologic 
studies reveal this detoxification strategy as the mechanistic basis for a threshold in the 
tumorigenesis of mutagenic carcinogens. 
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INTRODUCTION 
 
The possible existence of a threshold in 
chemical carcinogenesis is a matter of debate 
since decades (Littlefield et al., 1980, 
Purchase et al., 1995, Schaeffer, 1983, 
Schulte-Hermann et al., 2000). The relevance 
of this question resides in its importance for 
the extrapolation from short term 
experimental data employing high levels of 
exposure to life long low level exposure 
conditions usually encountered by human. 
The practical consequences are enormous 
(Hengstler et al., 2002, 2003, von Mach, 
2002). For non-threshold toxicants the 
necessity to attempt zero exposure is 
obvious. For threshold toxicants no toxicity 
occurs below the threshold concentration. 
Certain aspects of the enzymatic mechanism 
of the carcinogen-detoxifying enzyme 
epoxide hydrolase (EH) now imply the 
existence of such thresholds which is 
substantiated by experimental findings. 
  
22 
Xenobiotic metabolizing epoxide 
hydrolases play a pivotal role in the defense 
of the human body against the carcinogenic 
effects of epoxides (Arand et al., 2002, 
Hammock et al., 1997). These compounds 
(Fig. 1) frequently arise as metabolic 
intermediates from lipophilic foreign 
compounds in the course of their enzymatic 
transformation to more water soluble and 
hence excretable metabolites. Many epoxides 
are strong electrophiles and readily react with 
nucleophilic centers in the DNA, thereby 
leading to DNA adducts, mutations and, 
finally, cancer formation (Beland et al., 
1993).  
In contrast to many other xenobiotic 
metabolizing enzymes, epoxide hydrolases 
do not occur as a large family of isoenzymes. 
The majority of xenobiotic epoxides is 
hydrolyzed by a single EH, the endoplasmic 
reticulum resident microsomal epoxide 
hydrolase (mEH) (Oesch, 1973, Oesch et al., 
1976). There is one additional EH in human 
proficient for xenobiotic epoxide hydrolysis, 
the soluble epoxide hydrolase (sEH) that, in 
contrast to mEH, can take trans-substituted 
epoxides and is mainly responsible for the 
metabolism of fatty acid epoxides 
(Guenthner et al., 1981, Moghaddam et al., 
1997, Ota et al., 1980). 
 
 
 
 
Fig. 1 Structural diversity of mEH substrates. The range goes from very small epoxides 
such as the epichlorohydrin to complex bulky compounds such as the epoxides from 
androstene and benzo[a]pyrene. 
 
HOW TO COMBINE BROAD 
SUBSTRATE SPECIFICITY WITH 
HIGH AFFINITY? 
 
Here is the dilemma: on the one hand, 
the low complexity of the EH family 
demands a broad substrate specificity for 
structurally diverse compounds (Fig. 1) while 
on the other hand, a high affinity to these 
substrates is mandatory to efficiently remove 
these potentially genotoxic agents from the 
circulation already at low concentrations. 
This task for nature resembles the attempt to 
square the circle since it is to be expected 
that optimization towards one of these leads 
almost inevitably impairs the performance of 
the enzyme with respect to the other 
requirement.  
Recently, detailed insights in the 
enzymatic mechanism of epoxide hydrolysis 
(Fig. 2) have been obtained by kinetic 
(Armstrong, 1999, Lacourciere et al., 1993, 
Rink et al., 1998, Tzeng et al., 1996) and 
structural analysis (Arand et al., 1999b, 
Arand et al., 1996, Argiriadi et al., 1999, 
Laughlin et al., 1998, Nardini et al., 1999, 
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Tzeng et al., 1998, Zou et al., 2000) of the 
enzyme: Analysis of these data reveal the 
unique strategy that has evolved to fulfil the 
above demands conincidently.  
On the basis of their primary sequence, 
EHs have been grouped into the structural 
family of α/β hydrolase fold enzymes, 
leading to the previously unexpected 
recognition that EH-catalyzed epoxide 
hydrolysis proceeds via formation of an 
enzyme-substrate ester intermediate (Fig. 2B) 
(Arand et al., 1994, Lacourciere et al., 1994, 
Pries et al., 1994). Indeed, the ester 
intermediate could be isolated (Hammock et 
al., 1994, Müller et al., 1997) and kinetic 
analysis of mammalian and bacterial EH 
showed that the rate constant k11
                                                
 for the ester 
formation is several orders of magnitudes 
higher than the rate constant k2 for the 
subsequent hydrolysis (Rink et al., 1998, 
Tzeng et al., 1996), implying that the energy 
barrier ∆G1 (Fig. 2C) for the transition from 
the Michaelis Menten complex to the 
covalent intermediate is significantly lower 
than the activation energy ∆G2 for the 
subsequent hydrolysis of the ester. This has 
major consequences for the enzymatic 
efficacy. On the first sight, it results in a 
comparatively slow product formation, 
suggesting a poor performance of the 
enzyme. However, in the present case, 
substrate consumption and not product 
formation is crucial, since the aim is to 
remove the toxic species. In an enzymatic 
reaction involving a covalent intermediate 
the relationship between the Michaelis 
Menten constant Km and the dissociation 
constant KD is Km = KD · k2/(k1 + k2), which 
means that in the present case the ratio of Km 
to KD essentially equals the ratio of k2 to k1 
(k2 being orders of magnitude smaller than k1 
and therefore negligible in the sum k1 + k2). 
This mimics a high affinity of the enzyme to 
its substrates and strongly improves the 
clearance of low substrate concentrations as 
evidenced by computer simulation (Fig. 3). 
As long as the enzyme is well in excess of 
the substrate - indeed the usual situation 
since the mEH concentration in human liver 
is equivalent to 10 - 20 µM (Lu et al., 1979), 
and epoxides are usually present only in 
significantly lower concentrations and 
metabolically formed at moderate rates - 
most of the substrate is rapidly trapped as the 
covalent ester intermediate and thereby 
detoxified. This changes dramatically as soon 
as the epoxide  is in excess of the enzyme, eg 
if the formation rate of  the epoxide  exceeds 
the velocity of the enzymatic hydrolysis (Fig. 
3C). Thus, if a chemical carcinogen is 
metabolically activated to an epoxide that is 
inactivated by mEH, there can be a critical 
concentration of this compound where the 
formation rate starts to exceed the EH 
capacity. This is based on the general 
observation that the KD of the activating 
enzymes for the precursor substrate is 
significantly higher than that of the EH for 
the resulting epoxide, which is explained by 
the above mechanistic considerations. This 
turning point marks the practical threshold of 
the given carcinogen since from here the 
slope of the dose response curve changes 
dramatically (Fig. 3C).  
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1 Kinetic constants used in the text are defined by 
the following reaction scheme, where ES is the 
Michaelis-Menten complex (non-covalent association 
between enzyme and substrate) and E•S is the ester 
intermediate formed between enzyme and substrate 
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Fig. 2 Enzymatic mechanism of epoxide hydrolysis. A. Model of the active site of the human mEH, 
based on the structure of the related epoxide hydrolase from Aspergillus niger (Arand et al., 1999a, 
Zou et al., 2000), with the substrate styrene oxide prepositioned for nucleophilic attack. The model 
was built using O (Jones et al., 1991). The graphic representation was prepared from 
SwissPDBviewer (Guex et al., 1997) and subsequent rendering with POV-ray (http://www.povray.org) 
The course of the enzymatic reaction is outlined in B: Tyr374 and Tyr299 hydrogen bond to the 
epoxide oxygen, thereby positioning and further activating the epoxide for the nucleophilic attack by 
Asp226. The reaction between Asp226 and the epoxide leads to the enzyme substrate ester 
intermediate with inverse configuration as compared to the respective intermediate of esterases, i.e. 
the acid component of the ester stems from the enzyme and not from the substrate, in the present 
case. Subsequent hydrolysis is achieved by water activation through the His431/Glu404 charge relay 
system, leading to product formation and reconstitution of the active enzyme. C. Energy diagram of 
the enzymatic reaction, where ∆G0 is the activation energy of the uncatalyzed direct hydrolysis, ∆G1 is 
the activation energy for the enzyme-catalyzed ester formation and ∆G2 is the activation energy 
required for the enzyme-catalyzed ester hydrolysis. The observation that the first step, the formation of 
the enzyme-substrate covalent complex, is very fast, whilst the second step of the reaction is the slow, 
rate limiting step suggests some mobility of the catalytic nucleophile Asp226 in the side chain, which 
should facilitate ester formation with a broad range of substrates. At the same time, this implies that 
the position of the resulting ester bond in the covalent intermediate varies between different substrates 
and offers an explanation why the velocity of the second, hydrolytic step of the enzymatic reaction has 
not been optimized by nature (Arand et al., 1999b) to reach values like that of, eg acetyl choline 
esterase. 
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Fig. 3 Computer simulation of styrene 
epoxide hydrolysis by human 
microsomal epoxide hydrolase. A. The 
concentrations of free substrate (red line), 
the non-covalent Michaelis Menten 
complex between enzyme and substrate 
(pink line), the covalent ester intermediate 
between enzyme and substrate (orange 
line), and the terminal reaction product 
(diol; green line) are computed over time 
after addition of 1 µM styrene oxide into a 
single compartment. Rapid clearance is 
observed due to the essentially 
irreversible first step of the enzymatic 
mechanism, despite of the relatively low 
affinity of the enzyme to the substrate. In 
B, the area under the concentration-time 
curve (AUC) of styrene oxide is plotted as 
obtained from different simulation 
conditions. The red area represents the 
styrene oxide burden calculated assuming 
the above conditions. The yellow area 
plus the red and the orange area gives 
the AUC for styrene oxide that would 
result from a one step mechanism using 
the same dissociation constant and 
hydrolysis rate as for the two step 
simulation. It is three orders of magnitude 
above the AUC for the two-step 
mechanism and thus heavily exceeds the 
scale. The orange area indicates the 
amount of overestimation of styrene oxide 
burden with a two-step mechanism if 
simply calculated from the rate of product 
formation, which would result in a 3-fold 
underestimation of the detoxification 
efficacy of the EH, in the present case.  
C shows  the dependence of  steady state 
A
c [µM] 1,2
0,8
0,4
0
0 10 20 30
t [s]
B
c [µM] 1,5 
1 
0,5 
0 
concentration of styrene oxide from the rate of  styrene oxide  formation under the present 
conditions. Once the formation rate significantly rises above 3 µM x s-1, corresponding to 
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rises steeply. Above the maximum capacity, no EH-controlled equilibrium is possible. 
Computer simulation was performed using Microsoft Excel on a Macintosh G3 desktop 
computer. The respective spreadsheet containing the computations is available as additional 
material on the EXCLI website (http://www.giftinfo.uni-mainz.de/EXCLI/). Results obtained with 
this approach resembled those produced with the software package Kinsim (Barshop et al., 
1983), yet offer somewhat more flexibility, as long as the kinetics are kept simple. In order to 
match the experimental data available for the human mEH (Jenkins Sumner et al., 1994, Lu 
et al., 1979, Mendrala et al., 1993), mEH enzyme concentration, dissociation constant KD, 
rate constant k1 for the ester formation and the rate constant k2 for ester hydrolysis were set 
to 20 µM, 10 mM, 200 x s-1, and 0.2 x s-1, respectively. A slow back reaction from the ester 
to the epoxide that has recently been postulated by others on the basis of indirect evidence 
(Rink et al., 1998, Tzeng et al., 1996) is neglected in the present scenario because (i) it is 
energetically highly unfavoured in view of the new insights into the enzymatic mechanism 
and (ii) it complicates computation without qualitatively changing the outcome of the 
simulation. 
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DATA IN SUPPORT OF THE CONCEPT 
 
Experimental proof for the above 
deductions can be brought about by 
comparing the sensitivity of a recombinant 
mEH-expressing cell line towards a 
genotoxic agent - styrene oxide in the present 
case - with the respective sensitivity of the 
parental mEH-deficient cell line (Fig. 4). As 
predicted, the epoxide hydrolase-expressing 
cells were well-protected and tolerate high 
concentrations of the epoxide without 
apparent genotoxic effects. As soon as their 
capacity to enzymically trap the epoxide is 
exhausted, however, they show a steep 
increase in the biological effect caused by 
styrene oxide, which perfectly resembles the 
expectation based on the computer 
simulation.  
In addition to the experimental support, 
there is epidemiologic evidence for the 
correctness of our interpretation: styrene is a 
widely used precursor in the polymer 
industries and is produced in millions of tons 
per year. In human, most of the styrene is 
metabolically oxidized to the genotoxic 
styrene 7,8-oxide (Jenkins Sumner et al., 
1994).This intermediate is detoxified almost 
exclusively by EH, with a minute amount (< 
1%) being alternatively conjugated to 
glutathione. Despite the proven genotoxic 
effects of styrene oxide, it was recently 
reported that only a poor, if any, correlation 
could be found in human between 
occupational styrene exposure and genotoxic 
effects in peripheral blood monocytes 
(Rappaport et al., 1996). On the other hand, a 
significant correlation was found in the same 
individuals between styrene oxide exposure 
and genotoxic effects. The styrene oxide 
exposure level in this study was almost 1000-
fold below the styrene exposure level. This 
implies that the transient formation of styrene 
oxide from styrene in man is rapidly 
counteracted by EH and metabolically 
formed styrene oxide is efficiently kept from 
entering the systemic circulation. In contrast, 
minute amounts of the genotoxic agent, 
styrene-7,8-oxide, that reach systemic 
circulation before being detoxified by the 
mainly liver-resident mEH immediately exert 
their hazardous effects.  
In conclusion, the enzymatic mechanism 
of EH is the key to its success in efficiently 
detoxifying a broad range of structurally very 
different epoxides. Furthermore, the present 
study shows the existence of a threshold 
concentration for a classical carcinogen, 
styrene oxide, a situation which practically 
certainly also holds for other genotoxic 
carcinogens which act via intermediate 
epoxide formation.
  
 
  
27 
 
 0.15 elution rate [h-1] 
 
  
 
z 0.1  
 
 
 
 0.05 z 
 
 
z z z z 
0 
 1000 200 500
 
 styrene 7,8-oxide [µM] 
 
 
 
 
Fig. 4 Expression of human mEH protects V79 Chinese Hamster cells from styrene 
oxide-induced DNA damage and introduces a threshold. Parental mEH-deficient V79 
Chinese hamster cells (open circles) and a stable V79-derived cell line expressing human 
mEH (closed circles) (Herrero et al., 1997) were treated with increasing concentrations of 
styrene oxide in culture and the effect of the DNA damaging agent was assessed by alkaline 
filter elution of the DNA as described earlier (Hengstler et al., 1992). Human mEH expression 
was monitored by immunofluorescence analysis using an anti-mEH antiserum, as shown in 
the inserts (upper insert: parental V79 cells; lower insert: human mEH-expressing V79 cells). 
The onset of the genotoxic effect caused by styrene oxide in the recombinant cell line only at 
concentrations above 100 µM clearly demonstrates that mEH expression introduces a 
threshold for styrene oxide genotoxicity in V79 cells. Data points represent the average of 
three independent determinations. Error bars indicate the respective standard deviations. At 
a styrene oxide concentration of 500 µM, a strong cytotoxic effect on the parental V79 cells 
and a moderate toxic effect on the recombinant cells were observed. The respective data for 
the DNA elution rate are given for the sake of completeness but are off the linear range. 
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